Lead Investigator: Rebecca Dean, University of Sussex
Title of Proposal Research: The impact of interventions for depression on self-perceptions in young people: A systematic review and meta-analysis
Vivli Data Request: 8897
Funding Source: University of Sussex Psychology Doctoral Research Scholarship
Potential Conflicts of Interest: None
Summary of the Proposed Research:
Depression is the experience of persistent low mood, lasting for two weeks or more. Alongside feelings of sadness, those experiencing depression often have difficulties with their appetite, sleep, motivation, and self-esteem. Around one third of adolescents experience symptoms of depression, and around 8% of adolescents meet the criteria for a diagnosis of major depressive disorder.
This review aims to understand whether treatments for depression change how young people think about themselves. People with depression often see themselves in a negative way, and research has found that this negative view of self may be an important contributor to experiencing depression. Understanding more about whether treatments change how young people view themselves (i.e. do they make people view themselves more positively) will help us to know whether current treatments for depression are working as they should, and understand how we can improve treatments for depression in the future.
We will do this by pooling together the results of all studies that test treatments for symptoms of depression in young people (compared with either a group of young people who do not receive a treatment, or who receive a different kind of treatment), and measure how young people think about themselves. We will look at whether some treatments improve how young people view themselves more than others, and whether there are some aspects of how young people view themselves (e.g. self-esteem, self-concept) that are changed more than others by treatment.
A Multi-center, Double-blind, Placebo-Controlled Study of Paroxetine and Imipramine in Adolescents with Unipolar Major Depression – Continuation Phase.
Data Contributor: GlaxoSmithKline
Study ID: 29060/329_1
Sponsor ID: 29060/329_1